Crinetics Pharmaceuticals, Inc.·4

Jun 18, 5:23 PM ET

Okey Stephanie 4

4 · Crinetics Pharmaceuticals, Inc. · Filed Jun 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Crinetics (CRNX) Director Stephanie Okey Sells 6,900 Shares

What Happened Stephanie Okey, a director of Crinetics Pharmaceuticals (CRNX), sold a total of 6,900 shares in two open-market transactions on June 17, 2026. She sold 6,292 shares at a volume-weighted average price (VWAP) of $35.62 for proceeds of $224,121, and 608 shares at a VWAP of $36.22 for proceeds of $22,022 — total proceeds ≈ $246,143. These sales were reported on Form 4 filed June 18, 2026.

Key Details

  • Transaction date: June 17, 2026; Form 4 filed: June 18, 2026 (timely filing).
  • Trades: two open-market sales (reporting code S).
    • 6,292 shares at VWAP $35.62 (range $35.19–$36.06) — $224,121 (F2).
    • 608 shares at VWAP $36.22 (range $36.19–$36.29) — $22,022 (F3).
  • Total shares sold: 6,900; total proceeds ≈ $246,143.
  • Footnote: Sales were effected automatically under a Rule 10b5-1 trading plan adopted Nov 19, 2025 (F1).
  • Shares owned after the transaction: not specified in the provided filing; consult the full Form 4 or issuer for updated holdings.

Context These were sales, not purchases; sales executed under a pre-established 10b5-1 plan are typically routine and do not by themselves indicate a change in the insider's view of the company. No option exercises, gifts, or tax-withholding events were reported in this filing.

Insider Transaction Report

Form 4
Period: 2026-06-17
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-06-17$35.62/sh6,292$224,1217,008 total
  • Sale

    Common Stock

    [F1][F3]
    2026-06-17$36.22/sh608$22,0226,400 total
Footnotes (3)
  • [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
  • [F2]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
  • [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
Signature
/s/ Tobin Schilke, as attorney-in-fact|2026-06-18

Documents

1 file
  • 4
    wk-form4_1781817823.xmlPrimary

    FORM 4